$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 6 7 8 9 10 11 12 13 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | M | 0.00 | 367 | 0 | 367 | 0 to 367 |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 260.76 | 1,000 | 260,760 | 0 | 1,000 to 0 (-100.00 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 258.20 | 640 | 165,248 | 1,000 | 1.6 K to 1,000 (-39.02 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 0 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 260.76 | 1,000 | 260,760 | 7,464 | 8.5 K to 7.5 K (-11.81 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 258.12 | 1,000 | 258,115 | 8,464 | 9.5 K to 8.5 K (-10.57 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 9,464 | 7.5 K to 9.5 K (+26.80 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 1,330 | 0 | 0 | |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 325 | 0 | 1,656,258 | 1.7 M to 1.7 M (+0.02 %) |
| May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 1,330 | 0 | 1,655,933 | 1.7 M to 1.7 M (+0.08 %) |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 206,628 | |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 263.17 | 10,000 | 2,631,661 | 470,174 | 480.2 K to 470.2 K (-2.08 %) |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 480,174 | 470.2 K to 480.2 K (+2.13 %) |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Option Exercise | A | 264.12 | 6,467 | 1,708,064 | 6,467 | |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Option Exercise | A | 264.12 | 6,004 | 1,585,776 | 6,004 | |
| May 02 2014 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Grant | A | 0.00 | 4,923 | 0 | 4,923 | 0 to 4.9 K |
| Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
| Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 324 | 0 | 2,267 | 1.9 K to 2.3 K (+16.68 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 216,628 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 2,866 | 24,839 | 42,999 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 14,332 | 124,211 | 226,628 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 2.89 | 13,111 | 37,876 | 0 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 242.22 | 10,000 | 2,422,166 | 470,174 | 480.2 K to 470.2 K (-2.08 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 480,174 | 470.2 K to 480.2 K (+2.13 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 2,866 | 24,839 | 470,174 | 467.3 K to 470.2 K (+0.61 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 14,332 | 124,211 | 467,308 | 453 K to 467.3 K (+3.16 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 2.89 | 13,111 | 37,876 | 452,976 | 439.9 K to 453 K (+2.98 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 6,421 | 1,708,050 | 6,421 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 1,720 | 457,537 | 1,720 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Grant | A | 0.00 | 1,410 | 0 | 1,410 | 0 to 1.4 K |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 22,931 | 6,099,875 | 22,931 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 5,733 | 1,525,035 | 5,733 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Grant | A | 0.00 | 4,699 | 0 | 439,865 | 435.2 K to 439.9 K (+1.08 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 21.50 | 1,154 | 24,811 | 8,365 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 6,650 | 1,768,967 | 6,650 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 279.00 | 1,154 | 321,966 | 13,510 | 14.7 K to 13.5 K (-7.87 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 21.50 | 1,154 | 24,811 | 14,664 | 13.5 K to 14.7 K (+8.54 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Grant | A | 0.00 | 1,504 | 0 | 13,510 | 12 K to 13.5 K (+12.53 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 8,255 | 2,195,913 | 8,255 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Grant | A | 0.00 | 1,504 | 0 | 15,183 | 13.7 K to 15.2 K (+10.99 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 2,293 | 609,961 | 2,293 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 516 | 137,261 | 516 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Grant | A | 0.00 | 423 | 0 | 7,464 | 7 K to 7.5 K (+6.01 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 320.00 | 81,305 | 26,017,600 | 1,653,629 | 1.7 M to 1.7 M (-4.69 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 320.00 | 81,305 | 26,017,600 | 1,654,603 | 1.7 M to 1.7 M (-4.68 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 2,000 | |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 286.30 | 1,000 | 286,300 | 7,041 | 8 K to 7 K (-12.44 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 283.00 | 500 | 141,500 | 8,041 | 8.5 K to 8 K (-5.85 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 280.00 | 500 | 140,000 | 8,541 | 9 K to 8.5 K (-5.53 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 9,041 | 7 K to 9 K (+28.41 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 0.00 | 4,868 | 0 | 34,074 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 0.00 | 4,868 | 0 | 435,166 | 430.3 K to 435.2 K (+1.13 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 4,543 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 7,041 | 6.4 K to 7 K (+10.15 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,326 | 44,991 | 0 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 11,358 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 321.95 | 879 | 282,997 | 13,679 | 14.6 K to 13.7 K (-6.04 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 338.16 | 500 | 169,082 | 14,558 | 15.1 K to 14.6 K (-3.32 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 335.84 | 1,000 | 335,844 | 15,058 | 16.1 K to 15.1 K (-6.23 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 334.52 | 388 | 129,793 | 16,058 | 16.4 K to 16.1 K (-2.36 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 333.22 | 1,626 | 541,809 | 16,446 | 18.1 K to 16.4 K (-9.00 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 330.06 | 1,000 | 330,060 | 18,072 | 19.1 K to 18.1 K (-5.24 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,326 | 44,991 | 19,072 | 14.7 K to 19.1 K (+29.34 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 14,746 | 13.1 K to 14.7 K (+12.36 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 9,087 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 12,006 | 10.7 K to 12 K (+12.12 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 38,703 | |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,917 | 51,137 | 42,703 | |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 463.91 | 1,000 | 463,910 | 13,124 | 14.1 K to 13.1 K (-7.08 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 444.25 | 1,000 | 444,246 | 14,124 | 15.1 K to 14.1 K (-6.61 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 432.30 | 1,000 | 432,303 | 15,124 | 16.1 K to 15.1 K (-6.20 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 422.05 | 258 | 108,888 | 16,124 | 16.4 K to 16.1 K (-1.57 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 421.46 | 742 | 312,724 | 16,382 | 17.1 K to 16.4 K (-4.33 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 410.92 | 456 | 187,379 | 17,124 | 17.6 K to 17.1 K (-2.59 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 17,580 | 13.6 K to 17.6 K (+29.46 %) |
| Mar 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,917 | 51,137 | 13,580 | 8.7 K to 13.6 K (+56.76 %) |
| Mar 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 4,000 | |
| Mar 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 421.31 | 2,000 | 842,620 | 6,392 | 8.4 K to 6.4 K (-23.83 %) |
| Mar 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 8,392 | 6.4 K to 8.4 K (+31.29 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | M | 37.69 | 20,000 | 753,800 | 110,000 | |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 442.49 | 300 | 132,747 | 0 | 300 to 0 (-100.00 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 441.60 | 1,288 | 568,774 | 300 | 1.6 K to 300 (-81.11 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 440.63 | 812 | 357,791 | 1,588 | 2.4 K to 1.6 K (-33.83 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 439.94 | 502 | 220,849 | 2,400 | 2.9 K to 2.4 K (-17.30 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 438.45 | 898 | 393,732 | 2,902 | 3.8 K to 2.9 K (-23.63 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 436.77 | 1,960 | 856,077 | 3,800 | 5.8 K to 3.8 K (-34.03 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 435.70 | 1,140 | 496,701 | 5,760 | 6.9 K to 5.8 K (-16.52 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 434.57 | 1,949 | 846,975 | 6,900 | 8.8 K to 6.9 K (-22.03 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 433.47 | 7,027 | 3,046,012 | 8,849 | 15.9 K to 8.8 K (-44.26 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 432.84 | 1,724 | 746,218 | 15,876 | 17.6 K to 15.9 K (-9.80 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 431.34 | 339 | 146,223 | 17,600 | 17.9 K to 17.6 K (-1.89 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 429.96 | 361 | 155,214 | 17,939 | 18.3 K to 17.9 K (-1.97 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 428.51 | 700 | 299,956 | 18,300 | 19 K to 18.3 K (-3.68 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 427.05 | 500 | 213,524 | 19,000 | 19.5 K to 19 K (-2.56 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 426.06 | 500 | 213,028 | 19,500 | 20 K to 19.5 K (-2.50 %) |
| Mar 07 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Buy | M | 37.69 | 20,000 | 753,800 | 20,000 | 0 to 20 K |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,327 | 45,001 | 4,326 | |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 368.90 | 500 | 184,451 | 7,218 | 7.7 K to 7.2 K (-6.48 %) |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 368.02 | 2,400 | 883,246 | 7,718 | 10.1 K to 7.7 K (-23.72 %) |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 366.91 | 1,240 | 454,972 | 10,118 | 11.4 K to 10.1 K (-10.92 %) |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 365.37 | 1,632 | 596,279 | 11,358 | 13 K to 11.4 K (-12.56 %) |
| Feb 18 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,327 | 45,001 | 12,990 | 8.7 K to 13 K (+49.95 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 8.67 | 3,461 | 29,995 | 0 | |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 8.67 | 3,461 | 29,995 | 0 | |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 367.51 | 324 | 119,073 | 1,655 | 2 K to 1.7 K (-16.37 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 383.00 | 922 | 353,126 | 1,979 | 2.9 K to 2 K (-31.78 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 382.00 | 500 | 191,000 | 2,901 | 3.4 K to 2.9 K (-14.70 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 381.00 | 500 | 190,500 | 3,401 | 3.9 K to 3.4 K (-12.82 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 379.79 | 136 | 51,652 | 3,901 | 4 K to 3.9 K (-3.37 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 378.66 | 864 | 327,166 | 4,037 | 4.9 K to 4 K (-17.63 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 375.00 | 1,000 | 375,000 | 4,901 | 5.9 K to 4.9 K (-16.95 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 373.00 | 500 | 186,500 | 5,901 | 6.4 K to 5.9 K (-7.81 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 372.00 | 500 | 186,000 | 6,401 | 6.9 K to 6.4 K (-7.25 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 370.00 | 1,500 | 555,000 | 6,901 | 8.4 K to 6.9 K (-17.86 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 368.17 | 500 | 184,086 | 8,401 | 8.9 K to 8.4 K (-5.62 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 8.67 | 3,461 | 29,995 | 8,901 | 5.4 K to 8.9 K (+63.62 %) |
| Feb 14 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 8.67 | 3,461 | 29,995 | 5,440 | 2 K to 5.4 K (+174.89 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 385.04 | 52 | 20,022 | 2,282 | 2.3 K to 2.3 K (-2.23 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 385.00 | 1 | 385 | 2,334 | 2.3 K to 2.3 K (-0.04 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 384.77 | 1 | 385 | 2,335 | 2.3 K to 2.3 K (-0.04 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 384.33 | 7 | 2,690 | 2,336 | 2.3 K to 2.3 K (-0.30 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 374.09 | 1 | 374 | 2,343 | 2.3 K to 2.3 K (-0.04 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 373.34 | 100 | 37,334 | 2,344 | 2.4 K to 2.3 K (-4.09 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 324 | 0 | 2,444 | 2.1 K to 2.4 K (+15.28 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | M | 0.00 | 368 | 0 | 735 | |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 354.52 | 368 | 130,463 | 1,640 | 2 K to 1.6 K (-18.33 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | M | 0.00 | 368 | 0 | 2,008 | 1.6 K to 2 K (+22.44 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 324 | 0 | 2,304 | 2 K to 2.3 K (+16.36 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 324 | 0 | 1,979 | 1.7 K to 2 K (+19.58 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 6,000 | |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 310.04 | 500 | 155,020 | 6,392 | 6.9 K to 6.4 K (-7.25 %) |
| Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 307.00 | 500 | 153,500 | 6,892 | 7.4 K to 6.9 K (-6.76 %) |